We serve Chemical Name:4-bromo-N-(1,3-thiazol-2-yl)benzenesulfonamide CAS:331972-47-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-bromo-N-(1,3-thiazol-2-yl)benzenesulfonamide
CAS.NO:331972-47-5
Synonyms:4-bromo-benzenesulfonic acid thiazol-2-ylamide;4-Bromo-N-(thiazol-2-yl)benzenesulfonamide;4-Brom-benzolsulfonsaeure-thiazol-2-ylamid;HMS2648C17
Molecular Formula:C9H7BrN2O2S2
Molecular Weight:319.19800
HS Code:2935009090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:95.68000
Exact Mass:317.91300
LogP:3.86020
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-bromo-benzenesulfonic acid thiazol-2-ylamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,HMS2648C17 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-bromo-benzenesulfonic acid thiazol-2-ylamide Use and application,HMS2648C17 technical grade,usp/ep/jp grade.
Related News: Compared with individuals with cancer only, those with ASCVD and with ASCVD and cancer had a significantly higher presence of three of more of these factors (23 and 30 percent, respectively, versus 13 percent). 4-bromo-N-(1,3-thiazol-2-yl)benzenesulfonamide manufacturer The latest outbreak comes as China grapples with an African swine fever epidemic that has infected tens of thousands of pigs. It could stoke more worries among its people about the country��s food supply. 4-bromo-N-(1,3-thiazol-2-yl)benzenesulfonamide supplier Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL. 4-bromo-N-(1,3-thiazol-2-yl)benzenesulfonamide vendor Compared with individuals with cancer only, those with ASCVD and with ASCVD and cancer had a significantly higher presence of three of more of these factors (23 and 30 percent, respectively, versus 13 percent). 4-bromo-N-(1,3-thiazol-2-yl)benzenesulfonamide factory Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL.
